NASDAQ:SVRA - Savara Stock Price, Price Target & More

$9.21 +0.08 (+0.88 %)

(As of 04/20/2018 10:54 AM ET)

Previous Close$9.13

Today's Range$9.11 - $9.35

52-Week Range$4.60 - $17.19

Volume10,519 shs

Average Volume162,133 shs

Market Capitalization$287.38 million

P/E Ratio-5.19

Dividend YieldN/A

Beta0.04

About Savara (NASDAQ:SVRA)

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:SVRA

CUSIPN/A

Webwww.savarapharma.com

Phone512-961-1891

Debt

Debt-to-Equity Ratio0.13%

Current Ratio16.28%

Quick Ratio16.28%

Price-To-Earnings

Trailing P/E Ratio-5.19

Forward P/E Ratio-6.44

P/E GrowthN/A

Sales & Book Value

Annual Sales$130,000.00

Price / Sales2,167.89

Cash FlowN/A

Price / CashN/A

Book Value$3.91 per share

Price / Book2.36

Profitability

EPS (Most Recent Fiscal Year)($1.76)

Net Income$-29,790,000.00

Net MarginsN/A

Return on Equity-45.53%

Return on Assets-30.28%

Miscellaneous

Employees24

Outstanding Shares30,600,000

How to Become a New Pot Stock Millionaire

Savara (NASDAQ:SVRA) Frequently Asked Questions

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its earnings results on Wednesday, March, 14th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. View Savara's Earnings History.

What price target have analysts set for SVRA?

5 brokers have issued 1-year price objectives for Savara's shares. Their forecasts range from $20.00 to $35.00. On average, they anticipate Savara's stock price to reach $26.40 in the next twelve months. View Analyst Ratings for Savara.

What are Wall Street analysts saying about Savara stock?

Here are some recent quotes from research analysts about Savara stock:

1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (11/23/2017)
2. Canaccord Genuity analysts commented, "We see Savara’s work in NTM as meaningfully differentiated from other therapies as Molgradex is a non- antibiotic approach to treating lung NTMs and the product has potential to show efficacy in especially-hard-to-treat MABS infections where there are no viable pharmacological therapies available." (10/30/2017)

Who are some of Savara's key competitors?

Some companies that are related to Savara include AC Immune (ACIU), Rigel Pharmaceuticals (RIGL), Achaogen (AKAO), TiGenix - American Depositary Shares (TIG), Akebia Therapeutics (AKBA), Dicerna Pharmaceuticals (DRNA), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI), Insys Therapeutics (INSY), StemlineTherapeutics (STML), Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN), MediciNova (MNOV), ObsEva (OBSV), Isotechnika Pharma (AUPH), ProMetic Life Sciences (PFSCF), Zealand Pharma (ZEAL) and Innate Pharma (IPHYF).

Who are Savara's key executives?

Savara's management team includes the folowing people:

Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
David L. Lowrance, Chief Financial Officer (Age 50)
Nevan C. Elam, Independent Director (Age 49)
Richard J. Hawkins, Independent Director (Age 68)
Joseph S. McCracken Ph.D., Independent Director (Age 64)
Matthew Pauls J.D., Independent Director (Age 46)
Yuri Pikover, Independent Director (Age 56)

Has Savara been receiving favorable news coverage?

Media stories about SVRA stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Savara earned a coverage optimism score of 0.04 on Accern's scale. They also gave news articles about the company an impact score of 45.65 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $9.21.

How big of a company is Savara?

Savara has a market capitalization of $287.38 million and generates $130,000.00 in revenue each year. The company earns $-29,790,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Savara employs 24 workers across the globe.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]

MarketBeat Community Rating for Savara (SVRA)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		98 (Vote Outperform)
Underperform Votes:		104 (Vote Underperform)
Total Votes:		202

MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Savara (NASDAQ:SVRA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Savara in the last 12 months. Their average twelve-month price target is $26.40, suggesting that the stock has a possible upside of 186.64%. The high price target for SVRA is $35.00 and the low price target for SVRA is $20.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$26.40	$26.40	$26.40	$24.50
Price Target Upside:	186.64% upside	107.87% upside	77.54% upside	167.18% upside

Savara (NASDAQ:SVRA) Consensus Price Target History

Price Target History for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/9/2018	Canaccord Genuity	Set Price Target	Buy	$25.00	High
1/3/2018	Ladenburg Thalmann	Initiated Coverage	Buy -> Buy	$35.00	Medium
10/31/2017	Roth Capital	Lower Price Target	Buy	$40.00 -> $32.00	N/A
9/22/2017	Jefferies Group	Initiated Coverage	Buy -> Buy	$20.00	High
9/11/2017	JMP Securities	Initiated Coverage	Mkt Outperform -> Outperform	$20.00	High

(Data available from 4/20/2016 forward)

Savara (NASDAQ:SVRA) Earnings History and Estimates Chart

Earnings by Quarter for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.32)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.31)	($0.31)	($0.31)
Q2 2018	1	($0.33)	($0.33)	($0.33)
Q3 2018	1	($0.32)	($0.32)	($0.32)
Q4 2018	1	($0.36)	($0.36)	($0.36)

Savara (NASDAQ SVRA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Actual Revenue	Release Link	Conference Call
3/14/2018	Q4 2017	($0.2520)	($0.23)		View	Listen
11/8/2017	Q3 2017	($0.40)	($0.28)		View	N/A
8/9/2017	Q2 2017		($0.90)		View	N/A
5/9/2017	Q1 2017		($1.61)		View	N/A
3/6/2017	Q4 2016	($2.10)	($1.40)	$0.08 million	View	N/A
11/8/2016	Q3 2016	($3.50)	($2.80)	$0.05 million	View	N/A
8/9/2016	Q2 2016	($4.20)	($3.50)		View	N/A
5/6/2016	Q1 2016	($4.90)	($4.20)		View	N/A
3/14/2016	Q4 2015	($3.50)	($4.20)		View	N/A
11/12/2015	Q3 2015	($3.50)	($4.20)		View	N/A
8/12/2015	Q2 2015	($2.80)	($4.20)		View	N/A
5/11/2015	Q1 2015	($2.80)	($4.20)		View	N/A
3/24/2015	Q4 2014		($3.50)		View	N/A
10/31/2014	Q3 2014		($4.20)		View	N/A
8/11/2014	Q2 2014		($4.20)		View	N/A
5/5/2014	Q1 2014		($4.20)		View	N/A
3/26/2014	Q4 2013		($4.20)		View	N/A
11/4/2013	Q3 2013		($3.50)		View	N/A
8/5/2013	Q2 2013		($6.29)		View	N/A
5/15/2013	Q1 2013		($8.39)		View	N/A
3/19/2013	Q4 2012	($9.09)	($5.59)		View	N/A
11/5/2012	Q3 2012	($6.29)	($4.90)		View	N/A
8/6/2012	Q2 2012		($5.87)		View	N/A
5/7/2012	Q1 2012		($6.08)		View	N/A
3/7/2012	Q4 2011	($6.29)	($6.57)		View	N/A
11/7/2011	Q3 2011	($9.09)	($8.39)		View	N/A
8/8/2011	Q2 2011	($9.09)	($8.39)		View	N/A
5/9/2011	Q1 2011	($18.18)	($9.09)		View	N/A
3/10/2011	Q4 2010	($11.89)	($10.70)		View	N/A
11/8/2010	Q3 2010	($23.08)	($8.74)		View	N/A
8/6/2010	Q2 2010	($35.66)	($27.34)		View	N/A
4/30/2010	Q1 2010		($33.92)		View	N/A
3/16/2010	Q4 2009		($69.93)		View	N/A
11/10/2009	Q3 2009		($40.21)		View	N/A
8/12/2009	Q2 2009		($71.68)		View	N/A
5/12/2009	Q1 2009		($61.19)		View	N/A
3/25/2009	Q4 2008		($145.10)		View	N/A
11/6/2008	Q3 2008		($132.87)		View	N/A
8/11/2008	Q2 2008		($124.13)		View	N/A
5/12/2008	Q1 2008		($115.38)		View	N/A
3/13/2008	Q4 2007	($87.41)	($104.90)		View	N/A

(Earnings results data provided by Zacks Investment Research)

Savara (NASDAQ:SVRA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Savara (NASDAQ SVRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.93%
Institutional Ownership Percentage: 38.14%

Insider Trading History for Savara (NASDAQ:SVRA)

Institutional Ownership by Quarter for Savara (NASDAQ:SVRA)

Savara (NASDAQ SVRA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/29/2018	Yuri Pikover	Director	Buy	3,734	$9.00	$33,606.00	153,734
2/15/2018	David L Lowrance	CFO	Sell	7,000	$12.88	$90,160.00	33,994
2/15/2018	Jaakko Taneli Jouhikainen	Insider	Sell	25,000	$12.85	$321,250.00	219,216
10/27/2017	Yuri Pikover	Director	Buy	50,000	$7.85	$392,500.00	150,000
6/7/2017	David L Lowrance	CFO	Buy	2,100	$4.75	$9,975.00	2,100
6/7/2017	Jaakko Taneli Jouhikainen	Insider	Buy	10,500	$4.75	$49,875.00	235,326
6/7/2017	Joseph S Mccracken	Director	Buy	52,250	$4.75	$248,187.50	59,866

(Data available from 1/1/2013 forward)

Savara (NASDAQ SVRA) News Headlines

Source:

Date	Headline
	Savara (SVRA) Upgraded to "Sell" by BidaskClub www.americanbankingnews.com - April 12 at 10:21 AM
	Brokerages Anticipate Savara Inc (SVRA) to Post -$0.31 EPS www.americanbankingnews.com - April 11 at 7:18 PM
	Savara (SVRA) Given a $25.00 Price Target by Canaccord Genuity Analysts www.americanbankingnews.com - April 10 at 7:31 AM
	Savara Inc (SVRA) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 5 at 3:36 PM
	Savara (SVRA) Given New $32.00 Price Target at Roth Capital www.americanbankingnews.com - April 2 at 8:04 PM
	Savara Inc (SVRA) Director Yuri Pikover Buys 3,734 Shares www.americanbankingnews.com - April 2 at 1:22 PM
	Savara (SVRA) Lowered to "Buy" at BidaskClub www.americanbankingnews.com - March 30 at 2:18 PM
	BidaskClub Downgrades Savara (SVRA) to Strong Sell www.americanbankingnews.com - March 30 at 11:06 AM
	Report: Exploring Fundamental Drivers Behind Mast Therapeutics, Pebblebrook Hotel Trust, Smart, Waddell & Reed Financial, Quality Care Properties, and Meridian Waste Solutions — New Horizons, Emerging Trends, and Upcoming Developments finance.yahoo.com - March 30 at 8:14 AM
	Savara Inc to Post FY2019 Earnings of ($1.96) Per Share, Jefferies Group Forecasts (SVRA) www.americanbankingnews.com - March 19 at 7:46 AM
	Equities Analysts Issue Forecasts for Savara Inc's Q1 2018 Earnings (SVRA) www.americanbankingnews.com - March 16 at 7:56 AM
	Savara (SVRA) Posts Earnings Results, Beats Expectations By $0.02 EPS www.americanbankingnews.com - March 15 at 2:24 PM
	Savara's (SVRA) CEO Robert Neville on Q4 2017 Results - Earnings ... - Seeking Alpha seekingalpha.com - March 15 at 8:09 AM
	Savara to Present at 28th Annual Oppenheimer & Co. Healthcare Conference on March 20th finance.yahoo.com - March 15 at 8:09 AM
	Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update feeds.benzinga.com - March 14 at 4:55 PM
	Savara (SVRA) Initiates Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung Infection www.streetinsider.com - March 13 at 7:23 PM
	Savara Misses Endpoint, Stocks Tank www.baystreet.ca - March 13 at 7:23 PM
	Savara (SVRA) Initiates Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung Infection - StreetInsider.com www.streetinsider.com - March 13 at 8:16 AM
	Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection finance.yahoo.com - March 13 at 8:16 AM
	Savara Misses Endpoint, Stock Tanks www.baystreet.ca - March 12 at 6:45 PM
	Savara Inc (NASDAQ:SVRA): When Will It Breakeven? finance.yahoo.com - March 12 at 6:45 PM
	The Week Ahead In Biotech: Earnings, PDUFA Dates And More ... - Benzinga www.benzinga.com - March 12 at 8:28 AM
	Savara : Aironite Fails To Meet Primary Endpoint In Indie Phase 2 Study - Nasdaq www.nasdaq.com - March 12 at 8:28 AM
	SVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch - Nasdaq www.nasdaq.com - March 12 at 8:28 AM
	Savara (SVRA) Says Aironite Fails to Meet Primary Endpoint in Indie Phase 2 Clinical Study (Earlier) - StreetInsider.com www.streetinsider.com - March 12 at 8:28 AM
	Aironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research Network finance.yahoo.com - March 12 at 8:28 AM
	Savara Inc (SVRA) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - March 11 at 5:55 PM
	Calithera Biosciences (CALA) vs. Savara (SVRA) Head-To-Head Analysis www.americanbankingnews.com - March 8 at 5:55 AM
	Savara to Host Fourth Quarter & Fiscal Year End 2017 Financial Results and Business Update Conference Call on Wednesday March 14, 2018 finance.yahoo.com - March 7 at 8:11 AM
	Sectoral Asset Management Inc Invests $2.37 Million in Savara Inc (SVRA) Stock www.americanbankingnews.com - March 6 at 2:11 PM
	VHCP Management II LLC Buys Shares of 1,259,500 Savara Inc (SVRA) www.americanbankingnews.com - March 6 at 10:50 AM
	Savara (SVRA) Rating Lowered to Strong Sell at ValuEngine www.americanbankingnews.com - March 4 at 3:04 PM
	Brown Advisory Inc. Purchases New Holdings in Savara Inc (SVRA) www.americanbankingnews.com - March 2 at 5:08 AM
	BidaskClub Lowers Savara (SVRA) to Sell www.americanbankingnews.com - February 24 at 11:18 AM
	Savara Inc (SVRA) CFO David L. Lowrance Sells 7,000 Shares www.americanbankingnews.com - February 20 at 11:00 AM
	Savara Inc (SVRA) Insider Jaakko Taneli Jouhikainen Sells 25,000 Shares www.americanbankingnews.com - February 20 at 9:40 AM
	Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11th finance.yahoo.com - February 16 at 8:13 AM
	Investors Are Undervaluing Savara Inc (NASDAQ:SVRA) By 38.56%, Here Is My Intrinsic Value Calculation finance.yahoo.com - February 15 at 5:24 PM
	ValuEngine Upgrades Savara (SVRA) to "Sell" www.americanbankingnews.com - February 14 at 11:12 PM
	Savara Inc (SVRA) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - February 14 at 3:26 PM
	BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S. www.reuters.com - February 12 at 9:06 AM
	Savara (SVRA) Raised to Hold at BidaskClub www.americanbankingnews.com - February 10 at 8:50 AM
	Contrasting Proteon Therapeutics (PRTO) & Savara (SVRA) www.americanbankingnews.com - February 9 at 5:34 PM
	Savara Reports Publication of Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria finance.yahoo.com - February 6 at 8:49 AM
	Savara to Present at the 20th Annual BIO CEO & Investor Conference on February 12th finance.yahoo.com - February 5 at 8:58 AM
	Research Report Identifies Casella Waste, Savara Inc., Maximus, PCM, FARO Technologies, and Granite Point Mortgage Trust with Renewed Outlook Fundamental Analysis, Calculating Forward Movement finance.yahoo.com - January 30 at 8:46 AM
	Mast Therapeutics (SVRA) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - January 27 at 1:46 PM
	BidaskClub Downgrades Mast Therapeutics (SVRA) to Hold www.americanbankingnews.com - January 21 at 1:34 PM
	Mast Therapeutics, Inc. (SVRA) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - January 20 at 3:52 PM
	Mast Therapeutics (SVRA) Coverage Initiated at Ladenburg Thalmann Financial Services www.americanbankingnews.com - January 3 at 10:58 AM

Savara (NASDAQ:SVRA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Savara (NASDAQ:SVRA) Income Statement, Balance Sheet and Cash Flow Statement

Savara (NASDAQ SVRA) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff